Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 0 · 0%Moderate 1 · 33.3%High 1 · 33.3%

Adverse event · Patients with quiescent ulcerative colitis

Once‐daily dosing showed no clear difference in adverse event compared with conventional dosing (high certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.98 [0.92, 1.04]
8 studies · 3497 participants
High

Serious adverse events · Patients with quiescent ulcerative colitis

Once‐daily dosing showed no clear difference in serious adverse events compared with conventional dosing (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.2 [0.77, 1.87]
7 studies · 3196 participants
Moderate

Withdrawals due to adverse events · Patients with quiescent ulcerative colitis

It is very uncertain whether once‐daily dosing changes withdrawal due to adverse events compared with conventional dosing (very low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.18 [0.74, 1.89]
8 studies · 4340 participants
Very low